Navigation Links
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors
Date:2/15/2013

5 years
  • Related Milestones/catalysts in 2013-14
  • Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
  • Ongoing Clinical Trials of Companies Covered
  • Detailed reports on
  • SymBio pharma (4582, ¥488)

    Curis (CRIS, $2.99)

    Gilead (GILD, $40.36)

    Pharmacyclics (PCYC, $69.28) -

    Infinity pharma (INFI, $35.02)

    Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901

    Table of Contents

    Executive Summary

    Drugs in the Pipeline

    Phosphoinositide 3-Kinases (PI3Ks) inhibitors

    Scientific Rationale

    Dual inhibitors

    Bruton's Tyrosin Kinase (BTK) Inhibitors

    Scientific Rationale

    BTK inhibitors - Pipeline

    M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

    Kinase Inhibitor: Select M&A / Deals

    Upcoming Milestones Related in 2013-14

    Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

    Idelalisib (GS-1101) - Clinical Data

    Rigosertib - Clinical Data

    Other PI3K or Dual Inhibitors - Clinical Data

    Combination Studies of
    '/>"/>

    SOURCE Bharat Book Bureau
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Womens Health Expert GC-Rise Ties up with Georgetown MBA Team to Tap M&A Potential and Growth Strategy
    2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
    3. Kinase Inhibitors: Global Markets -- Focus on the U.S.
    4. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
    5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
    6. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... June 30, 2015  The University of California, ... (CCE/Bio) and UC San Diego Extension announced their ... held Aug.  12 – 14, 2015, at UC ... workshop provides an intense exposure to best practices ... is well-suited to biologists, process engineers and business ...
    (Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
    Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
    ... Omthera Pharmaceuticals, Inc., a privately-held emerging ... of a randomized, open-label, four-way cross-over pharmacokinetics ... Omthera,s lead compound for the treatment of ... the leading prescription Omega-3.  Epanova is an ...
    ... Nov. 8, 2010 Solutia Inc. (NYSE: ... sold its Perkalink® business and entered into a ... to LANXESS, a Germany-based specialty chemicals company.   ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO) "The sale ...
    ... in Europe Could Be Prevented -- PRAGUE, November 8, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
    Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 2Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 2Study Shows Cardiovascular Deaths in Europe Could Be Prevented 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 4Study Shows Cardiovascular Deaths in Europe Could Be Prevented 5Study Shows Cardiovascular Deaths in Europe Could Be Prevented 6Study Shows Cardiovascular Deaths in Europe Could Be Prevented 7Study Shows Cardiovascular Deaths in Europe Could Be Prevented 8Study Shows Cardiovascular Deaths in Europe Could Be Prevented 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 10
    (Date:6/9/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, will be providing demonstrations of its ... 2015 Drug Information Association (DIA) Annual Meeting in ... presentations will include previews of many exciting new enhancements ... iMedNet 2015 Feature 1 Release. ...
    (Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: ... that clinical data featuring its Precision Cancer Monitoring SM ... and Liquid Biopsies conference in San Diego, CA ... AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... on June 13-16. "We continue to advance ...
    (Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
    Breaking Biology News(10 mins):MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
    ... and lifestyle offers significant benefits to people with chronic ... Dietitian Katrina Campbell, who graduated with her PhD ... at the Royal Brisbane and Women,s Hospital (RB&WH) and ... thesis. Dr Campbell said depending on the patient,s ...
    ... to manage some of Florida,s most popular sport fish, ... Effective Strategies for the Management of Sustainable Fisheries: Biology ... Ault, an assistant professor in the Division of ... has a unique high-tech tagging approach to studying tarpon ...
    ... PatientSecure(TM) on Display at Leading Healthcare Conference, ... 20 Identity,management in a busy healthcare ... especially when it must be repeated with ... Inc., a leading supplier of,innovative computer products, ...
    Cached Biology News:Diet support helps chronic kidney patients 2New tarpon, bonefish compendium published 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4
    ... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
    Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
    Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
    Request Info...
    Biology Products: